Atuhani S Burnett1, Patrick L Quinn2, Dare V Ajibade3, Stephen R Peters4, Sushil K Ahlawat5, Omar M Mahmoud6, Ravi J Chokshi7. 1. Banner MD Anderson Cancer Center, Division of Surgical Oncology, Greeley, CO, USA. Electronic address: atuhani@yahoo.com. 2. Rutgers New Jersey Medical School, Division of Surgical Oncology, Newark, NJ, USA. Electronic address: plq3@njms.rutgers.edu. 3. Rutgers New Jersey Medical School, Division of Surgical Oncology, Newark, NJ, USA. Electronic address: drdvajibade@gmail.com. 4. Rutgers New Jersey Medical School, Department of Pathology, Newark, NJ, USA. Electronic address: peterssr@njms.rutgers.edu. 5. Rutgers New Jersey Medical School, Department of Gastroenterology, Newark, NJ, USA. Electronic address: ahlawasu@njms.rutgers.edu. 6. Rutgers Cancer Institute of New Jersey, Department of Radiation Oncology, New Brunswick, NJ, USA. Electronic address: omm21@cinj.rutgers.edu. 7. Rutgers New Jersey Medical School, Division of Surgical Oncology, Newark, NJ, USA. Electronic address: chokshrj@njms.rutgers.edu.
Abstract
BACKGROUND: Challenges still exist in differentiating pancreatic adenocarcinoma from benign disease. The use of adjuvant testing of tissue biopsies has demonstrated potential diagnostic value. We designed a proof of concept study to first validate four individual immunohistochemistry biomarkers and then combine them into a panel to boost overall diagnostic sensitivity. METHODS: Malignant and benign pancreas from 27 pancreaticoduodenectomy specimens underwent immunohistochemistry staining with VHL, IMP3, S100A4, S100P. Using ROC curve analysis, threshold criteria for number of cells staining were chosen for each biomarker. Biomarkers were then evaluated as a panel for their ability to discriminate malignant from benign specimens. RESULTS: Diagnostic sensitivity of VHL, IMP3, S100A4, and S100P were 75.0%, 79.2%, 45.8%, and 0%. When VHL, IMP3, and S100A4 were grouped into a panel, they were able to distinguish cancer from normal tissue with a sensitivity of 100% and a specificity of 96%. CONCLUSIONS: The high diagnostic value of an IHC panel consisting of VHL, IMP3, and S100A4 on surgical specimens suggests the need for future prospective studies of these biomarkers on biopsy specimens.
BACKGROUND: Challenges still exist in differentiating pancreatic adenocarcinoma from benign disease. The use of adjuvant testing of tissue biopsies has demonstrated potential diagnostic value. We designed a proof of concept study to first validate four individual immunohistochemistry biomarkers and then combine them into a panel to boost overall diagnostic sensitivity. METHODS: Malignant and benign pancreas from 27 pancreaticoduodenectomy specimens underwent immunohistochemistry staining with VHL, IMP3, S100A4, S100P. Using ROC curve analysis, threshold criteria for number of cells staining were chosen for each biomarker. Biomarkers were then evaluated as a panel for their ability to discriminate malignant from benign specimens. RESULTS: Diagnostic sensitivity of VHL, IMP3, S100A4, and S100P were 75.0%, 79.2%, 45.8%, and 0%. When VHL, IMP3, and S100A4 were grouped into a panel, they were able to distinguish cancer from normal tissue with a sensitivity of 100% and a specificity of 96%. CONCLUSIONS: The high diagnostic value of an IHC panel consisting of VHL, IMP3, and S100A4 on surgical specimens suggests the need for future prospective studies of these biomarkers on biopsy specimens.